William Blair Issues Positive Forecast for Medpace Earnings

Medpace Holdings, Inc. (NASDAQ:MEDP) – Investment analysts at William Blair upped their FY2024 earnings per share estimates for Medpace in a note issued to investors on Tuesday, October 22nd. William Blair analyst M. Smock now anticipates that the company will post earnings per share of $11.83 for the year, up from their prior forecast of $11.55. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Medpace’s current full-year earnings is $11.64 per share. William Blair also issued estimates for Medpace’s Q1 2025 earnings at $2.92 EPS, Q3 2025 earnings at $3.18 EPS, Q4 2025 earnings at $3.19 EPS and FY2025 earnings at $12.35 EPS.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, October 21st. The company reported $3.01 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.24. The business had revenue of $533.32 million for the quarter, compared to analyst estimates of $540.99 million. Medpace had a net margin of 16.74% and a return on equity of 55.14%. The firm’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.22 earnings per share.

A number of other equities analysts also recently weighed in on the company. Truist Financial lowered their price target on Medpace from $415.00 to $397.00 and set a “hold” rating on the stock in a research report on Monday, October 14th. TD Cowen dropped their price target on Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a research note on Wednesday. UBS Group downgraded Medpace from a “buy” rating to a “neutral” rating and cut their price target for the company from $420.00 to $350.00 in a report on Friday, September 27th. Redburn Atlantic assumed coverage on shares of Medpace in a report on Monday, October 14th. They issued a “buy” rating and a $404.00 price objective on the stock. Finally, Guggenheim cut their target price on shares of Medpace from $464.00 to $432.00 and set a “buy” rating for the company in a research note on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, Medpace currently has a consensus rating of “Hold” and an average target price of $380.00.

Medpace Trading Up 1.1 %

NASDAQ MEDP opened at $330.07 on Thursday. The company has a market cap of $10.23 billion, a PE ratio of 33.65, a PEG ratio of 1.77 and a beta of 1.35. Medpace has a 12 month low of $239.00 and a 12 month high of $459.77. The stock has a 50 day moving average of $353.71 and a 200-day moving average of $382.20.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Mather Group LLC. acquired a new stake in Medpace during the first quarter worth approximately $28,000. Fidelis Capital Partners LLC acquired a new position in Medpace in the first quarter valued at about $31,000. J.Safra Asset Management Corp raised its stake in Medpace by 87.0% in the first quarter. J.Safra Asset Management Corp now owns 101 shares of the company’s stock valued at $41,000 after purchasing an additional 47 shares in the last quarter. DT Investment Partners LLC bought a new stake in Medpace during the second quarter worth about $41,000. Finally, Ashton Thomas Private Wealth LLC acquired a new stake in Medpace during the second quarter worth about $52,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.